Clinical trials: pulmonary fibrosis, open to volunteers
Pulmonary Fibrosis
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
The purposes of this study are: to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; to determine if specific genetic traits account for differing patterns of…
- Trial name
- GP (NCT00258570)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Fibrosis
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary…
- Trial name
- NCT07284459
- Testing
- PIPE-791 Dose A, PIPE-791 Dose B
- Where
- 108 sites in Argentina, Australia and 17 more
- Volunteers
- 324 people
- Sponsor
- Contineum Therapeutics
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
- Trial name
- NCT07333183
- Testing
- inhaled mosliciguat, Dry Powder Inhaler
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if…
- Trial name
- FIBROPOC (NCT06714123)
- Testing
- Senicapoc
- Where
- 5 sites in Denmark, Estonia and 1 more
- Volunteers
- 140 people
- Sponsor
- Vejle Hospital
Cystic Fibrosis (CF), Bronchiectasis Adult
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate.
- Trial name
- NOVEL (NCT07289100)
- Testing
- Non-Interventional Study
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Glucose Metabolism Disorders in Cystic Fibrosis
Reproducibility of Continuous Glucose Monitoring (CGM) in the Assessment of Glucose Metabolism Disorders in Children With Cystic Fibrosis
Glucose metabolism disorders in cystic fibrosis (CF-GMD) are common and have a negative clinical impact. Screening currently relies on the oral glucose tolerance test (OGTT); however, this procedure is burdensome and complex for…
- Trial name
- CGMUCODIAB (NCT07851831)
- Testing
- Continuous Glucose Monitoring, Eating Habits Questionnaire, Use of an actigraphy watch
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances.
- Trial name
- NCT07820254
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Pulmonary Fibrosis
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases
Organ fibrosis is a common end-stage pathological change in various chronic diseases, characterized by excessive deposition of extracellular matrix (ECM) and disruption of tissue architecture, which can involve multiple organs…
- Trial name
- NCT07459205
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events.
- Trial name
- MERCURION-IPF (NCT07299695)
- Testing
- Intravenous immunoglobulin (IVIG), Usual treatment
- Where
- Greece
- Volunteers
- 196 people
- Sponsor
- Argyrios Tzouvelekis
Fibroadenoma, Breast Fibroadenoma
Management of Breast Fibroadenoma: Comparing Observation, Microwave Ablation, and Surgical Excision
The purpose of this study is to evaluate and compare three different management strategies for benign breast fibroadenoma: conservative management with clinical and radiological follow-up (observation), ultrasound-guided…
- Conditions
- Fibroadenoma, Breast Fibroadenoma, Benign Breast Disease
- Trial name
- NCT07890766
- Testing
- Ultrasound-guided percutaneous microwave ablation, Conventional open surgical excision
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
Pulmonary NTM infection is recognized as one of the most challenging infections to treat among people with cystic fibrosis (PwCF), notable for prolonged treatment courses and often poor response to therapy.
- Trial name
- pHALT NTM (NCT05686837)
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Idiopathic Pulmonary Fibrosis
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can…
- Trial name
- NCT06567717
- Testing
- Zinc, Nicotinamide riboside
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cedars-Sinai Medical Center
Cystic Fibrosis
Evaluation of New Device for Beta-adrenergic Sweat Test in the Context of Stratification of Patient With Cystic Fibrosis
This is a clinical study to evaluate a new medical system used to perform a sweat secretion-based test for the diagnosis of cystic fibrosis.
- Trial name
- BESTRACYFIC (NCT06836453)
- Testing
- Sweat stimulation and secretion quantification
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
The CF-Tracker study is a community surveillance study, designed to understand the causes of exacerbations in people with cystic fibrosis (CF) (pwCF).
- Trial name
- CF-Tracker (NCT06940531)
- Where
- 18 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Alexander Horsley
Cystic Fibrosis
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of…
- Trial name
- NCT05998629
- Testing
- a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels, Standard of Care laboratory procedure for measurement of sweat
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Pulmonary Fibrosis, Interstitial Lung Disease
Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This retrospective observational study evaluates the diagnostic performance of AccuPulmo CT Portal, an artificial intelligence-assisted medical imaging software, for detecting pulmonary fibrosis on pre-existing chest computed…
- Trial name
- ACCUPULMO-FIBR (NCT07761377)
- Testing
- AccuPulmo CT Portal
- Where
- Taiwan
- Volunteers
- 900 people
- Sponsor
- Taichung Veterans General Hospital
Cystic Fibrosis
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
The purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations.
- Trial name
- Nof1 (NCT04580368)
- Testing
- CFTR Modulators
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation (3849 +10kb C-->T).
- Trial name
- NCT06429176
- Testing
- SPL84
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- SpliSense Ltd.
Cystic Fibrosis, Non-CF Bronchiectasis
Regional Phenotyping of CF and Non-CF Bronchiectasis
The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy…
- Trial name
- NCT04793867
- Testing
- Xenon
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Interstitial Lung Disease, Sarcoidosis
Interstitial Lung Disease Research Unit Biobank
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Trial name
- ILDRU (NCT05392881)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Kansas Medical Center